UBS announced a net profit of $1.4 billion for the second quarter of 2019.Earningsread more
Japan and South Korea are part of a complex and tightly linked supply chain that produces electronic goods such as smartphones and laptops.Technologyread more
Michael Kugelman from the U.S.-based Wilson Center says other issues take precedence in the bilateral dialogue between the United States and Pakistan — namely, Afghanistan and...Asia Politicsread more
Beijing says it can still meet its 2019 growth target of between 6% and 6.5% and continues to roll out stimulus measures to prop up activity. China set a 2019 industrial...China Economyread more
A different oil pricing dynamic has been evolving with new supply calculations based on the U.S. as the world's largest producer.Market Insiderread more
The Massachusetts senator's alarm-sounding on consumer debt neglects to measure it against the growth in the economy and the ability to pay.Economyread more
Stocks in Asia Pacific edged up on Tuesday afternoon, as investors await closely-watched central bank meetings in the coming days.Asia Marketsread more
More than half of Venezuela's 23 states lost power on Monday, according to Reuters witnesses and reports on social media, a blackout the government blamed on an...World Politicsread more
Equifax will give consumers a range of options for monitoring their credit or making claims of fraud or data misuse, part of a $425 million restitution fund.Technologyread more
The deal between the White House and Democrats was earlier expected to raise the debt ceiling for two years and permanently end the sequester.Politicsread more
Britain's Antstream is jumping into the cloud gaming battle with a streaming platform for retro titles. And Tencent just backed the company.Technologyread more
Shares of Teva Pharmaceuticals fell as much as 6 percent on Wednesday after the U.S. Patent Office invalidated two of the company's patents.
Mylan had filed a total of four claims related to Copaxone 40 mg. The two patents invalidated on Wednesday are owned by Yeda Research & Development and licensed to Teva. The involved parties are still waiting on a ruling for a third patent, which is expected by Sept. 1.
Earlier this month, the Patent Office had ruled that a fourth patent was not eligible for review due to procedural reasons. On Wednesday, Mylan said that it believes the favorable rulingundermines that earlier judgement. The company said it will be "pursuing all avenues to challenge" the earlier patent.
Teva CEO Erez Vigodman said in a statement, "We remain confident in the strength of our intellectual property surrounding COPAXONE 40mg." He also said that the company is "prepared to defend the full suite of our intellectual property... regardless of the time required."
Teva also said it plans to appeal the decision in the U.S. Court of Appeals for the Federal Circuit.
The stock recovered some losses and closed about 3 percent lower.